CA

CanBas Co.,Ltd.

A clinical-stage biopharmaceutical company developing novel cancer therapeutics.

4575 | T

Overview

Corporate Details

ISIN(s):
JP3244570002
LEI:
Country:
Japan
Address:
沼津市大手町二丁目2番1号

Description

CanBas is a clinical-stage biopharmaceutical company dedicated to the research and development of novel therapeutics for cancer patients. The company focuses on drug discovery in the field of oncology, including immuno-oncology and treatments targeting the cell cycle. Its pipeline includes CBP501, a calmodulin-modulating peptide that has undergone Phase II clinical trials. CanBas leverages proprietary screening systems and core technologies to develop innovative anti-cancer agents, with a focus on creating treatments with potentially fewer side effects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 08:46
確認書
Japanese 8.1 KB
2025-09-29 08:46
有価証券報告書-第26期(2024/07/01-2025/06/30)
Japanese 576.6 KB
2025-02-13 07:55
確認書
Japanese 8.1 KB
2025-02-13 07:54
半期報告書-第26期(2024/07/01-2025/06/30)
Japanese 160.4 KB
2024-09-30 08:04
臨時報告書
Japanese 22.7 KB
2024-09-27 08:21
内部統制報告書-第25期(2023/07/01-2024/06/30)
Japanese 21.7 KB
2024-09-27 08:21
確認書
Japanese 8.1 KB
2024-09-27 08:20
有価証券報告書-第25期(2023/07/01-2024/06/30)
Japanese 637.2 KB
2024-05-10 08:16
確認書
Japanese 8.1 KB
2024-05-10 08:16
四半期報告書-第25期第3四半期(2024/01/01-2024/03/31)
Japanese 134.6 KB
2024-02-09 08:13
確認書
Japanese 8.0 KB
2024-02-09 08:12
四半期報告書-第25期第2四半期(2023/10/01-2023/12/31)
Japanese 163.0 KB
2023-11-10 08:00
確認書
Japanese 8.0 KB
2023-11-10 07:51
四半期報告書-第25期第1四半期(2023/07/01-2023/09/30)
Japanese 134.0 KB
2023-09-27 08:08
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all CanBas Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CanBas Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CanBas Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.